Lisata Therapeutics, Inc. (LSTA) stock
LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.21−0.07 (-5.47%)
Close on Nov 13, 2026Market cap $10.90MP/E –Yield –
Earnings
Lisata Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2025
$70.00K
EPS, Q2 FY2025
–
-$0.61 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Lisata Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $70.00K | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | – | – | -$0.59 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024after the close | – | – | -$0.61 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | -$0.65 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | – | – | -$0.65 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | – | – | -$0.50 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | – | – | -$0.77 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023after the close | – | – | -$0.76 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | – | – | -$7.88 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 5, 2022after the close | – | – | -$0.11 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | – | – | -$0.07 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 22, 2022after the close | – | – | -$0.11 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | – | – | -$0.12 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 13, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 7, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 5, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 6, 2019after the close | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 8, 2019after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Lisata Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Lisata Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Lisata Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- News
- Results
- Results
- Update
- Results
- Results
- News
- News
- Update
- Update
- Results
See a number that looks wrong?